Omeros Corporation (OMER)
Automate Your Wheel Strategy on OMER
With Tiblio's Option Bot, you can configure your own wheel strategy including OMER - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol OMER
- Rev/Share 0.0071
- Book/Share -3.6784
- PB -0.8971
- Debt/Equity -0.54
- CurrentRatio 1.1557
- ROIC -1.0456
- MktCap 193355250.0
- FreeCF/Share -2.4633
- PFCF -1.352
- PE -1.2515
- Debt/Assets 0.4904
- DivYield 0
- ROE 0.9073
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | OMER | D. Boral Capital | -- | Buy | -- | $36 | Dec. 23, 2024 |
News
Down 54.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Omeros (OMER)
Published: June 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Omeros (OMER) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Read More
Omeros Corporation Announces Agreements to Acquire $80.5 Million of its Convertible Senior Notes Due 2026
Published: May 12, 2025 by: Business Wire
Sentiment: Neutral
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) (“Omeros” or the “Company”) today announced that it has entered into exchange agreements (the “Exchange Agreements”) with a limited number of investors who are holders of the Company's 5.25% Convertible Senior Notes due 2026 (the “2026 Convertible Notes”) to exchange, on a one-for-one basis, $70.5 million aggregate principal amount of the 2026 Convertible Notes for newly issued 9.50% Convertible Senior Notes due 2029, with a conversion.
Read More
Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros' Proprietary OncotoX-AML Clinical Program
Published: April 10, 2025 by: Business Wire
Sentiment: Neutral
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced the establishment of the Omeros Oncology Clinical Steering Committee to advance Omeros' OncotoX biologics program focused on acute myeloid leukemia (AML). AML is the most fatal form of leukemia and accounts for approximately 80 percent of acute leukemias in adults and one-third of all cancers affecting the blood/bone marrow, representing a high unmet need. Omeros' OncotoX program for AML consists of proprietary targeted.
Read More
Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program
Published: March 21, 2025 by: Business Wire
Sentiment: Neutral
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today reported that clinical trial site activation for enrollment is underway for the company's Phase 3 program evaluating zaltenibart in paroxysmal nocturnal hemoglobinuria (PNH). Zaltenibart (OMS906) is Omeros' investigational inhibitor of MASP-3, the key and most proximal activator of the alternative pathway of complement. Zaltenibart inhibits the intravascular hemolysis treated by C5 inhibitors as well as the extravascular hemolysi.
Read More
Omeros Corporation: Scientifically Compelling Again, But The Delay Has Cost Us
Published: February 24, 2025 by: Seeking Alpha
Sentiment: Positive
Omeros Corporation's stock rebounded after successful data analysis for narsoplimab, showing 68% lower death risk in HSCT-TMA patients compared to historical controls. FDA requested new statistical analysis for narsoplimab's BLA resubmission, which proved successful, leading to a potential approval by late 2025. Financial risks include limited cash runway and potential market constraints due to upcoming generic competition and insurance issues.
Read More
About Omeros Corporation (OMER)
- IPO Date 2009-10-08
- Website https://www.omeros.com
- Industry Biotechnology
- CEO Dr. Gregory A. Demopulos M.D.
- Employees 202